I don't see it as a 'big' setback. Perhaps a little disappointing that leronlimab isn't first to market. As NP said (which is the same reason why I am 100% sure), all the 'anecdotal' data from EIND patients are indicative of excellent efficacy. Plus, I think CYDY is best situated with drug supply. So while not first out the gates, we stand to be the first to collect the most money and its not like the government is running out of cash.